Immunogenicity to biologics: mechanisms, prediction and reduction.
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsStructure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein.Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.Golimumab pharmacokinetics in ulcerative colitis: a literature reviewChallenges and approaches for the development of safer immunomodulatory biologics.The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Review on modeling anti-antibody responses to monoclonal antibodies.Biologic concentration testing in inflammatory bowel disease.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Design and engineering of deimmunized biotherapeutics.Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies.The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.Pharmacokinetics of Monoclonal Antibodies.Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.Quartz crystal microbalance as an assay to detect anti-drug antibodies for the immunogenicity assessment of therapeutic biologics.Trends in Malignant Glioma Monoclonal Antibody Therapy.Immunohistochemical Investigations of Treatment with Ro 13-3978, Praziquantel, Oxamniquine, and Mefloquine in Schistosoma mansoni-Infected Mice.Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model.Aminopeptidase secreted by Chromobacterium sp. Panama inhibits dengue virus infection by degrading the E protein.
P2860
Q26766424-8D432241-19DB-41F4-9FDD-9ABF4FC8F6BBQ26785537-5BFA6CEF-49A3-4932-88D3-D41F05B6A8FDQ35844550-69883C28-F022-4C2F-8DA3-248E23A3148BQ36832755-E69C0F7A-EC9E-4B5E-8534-E83DBC0749F6Q37383419-FB484086-9F6F-42F8-AE0D-9B36CF0A3332Q37671983-22855D7B-2465-4C76-99E4-4DBE9A592D32Q38093772-0AE58C1E-D2AE-4935-AE15-DA0D9C72CC50Q38129037-93466A16-CCB0-4398-A8D9-5A3E339827DCQ38151885-0659B3BE-5648-48CE-A259-D470BAD40F1BQ38229813-185905F9-AB0D-4CDF-BB20-9F00182401EBQ38319306-BC072104-FAB2-49AC-B313-3D2C7F427DB7Q38537167-410E8F7C-258B-406C-B3AE-A801AE361234Q38631012-EBE51417-20C0-4475-9371-6BC1C1F33386Q38870681-AAFA12C9-4F68-4AAD-B92F-9C249A3C9A4AQ38946563-2CC95DD6-7317-408A-B829-F547CCA4E339Q41181813-14E3268A-0CCA-4177-B067-98F6C12124B8Q41953123-8789C935-8EE7-448B-9D1B-5EE536D58E1DQ42118646-1DB6959A-0FDE-4D2C-BFC3-7037646FBB3FQ47291079-E84FA5BE-0DE8-40A7-9C84-49E08F578726Q47449187-3B6CBC91-AB24-4395-B37E-52BBC2C90899Q54942652-C1F74D1E-3495-41FB-8AF5-D635DAFBA086Q55112826-C28FEE6B-648B-40ED-B450-A9914CA771CDQ55114408-48F2160E-5C61-4AB0-8136-D31466D96AD3Q55209557-2A5C7C25-BDE4-41F8-8F76-29D342285F83
P2860
Immunogenicity to biologics: mechanisms, prediction and reduction.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immunogenicity to biologics: mechanisms, prediction and reduction.
@ast
Immunogenicity to biologics: mechanisms, prediction and reduction.
@en
Immunogenicity to biologics: mechanisms, prediction and reduction.
@nl
type
label
Immunogenicity to biologics: mechanisms, prediction and reduction.
@ast
Immunogenicity to biologics: mechanisms, prediction and reduction.
@en
Immunogenicity to biologics: mechanisms, prediction and reduction.
@nl
prefLabel
Immunogenicity to biologics: mechanisms, prediction and reduction.
@ast
Immunogenicity to biologics: mechanisms, prediction and reduction.
@en
Immunogenicity to biologics: mechanisms, prediction and reduction.
@nl
P2093
P2860
P50
P1476
Immunogenicity to biologics: mechanisms, prediction and reduction.
@en
P2093
Karthik Govindappa
Kevin Park
Mohammad Alhaidari
P2860
P2888
P304
P356
10.1007/S00005-012-0189-7
P577
2012-08-29T00:00:00Z
P6179
1046284586